Vidion system CE marked
This article was originally published in Clinica
Fremont, California-based NeoVista has CE marked its Vidion wet age-related macular degeneration (AMD) therapy for sale in Europe. Vidion is an epimacular brachytherapy device which uses strontium 90 to target ionising beta radiation to choroidal neovascularisation – new blood vessels that have grown in connective tissue surrounding the eye. Blood leaking from this neovascularisation affects central vision, causing AMD.